Literature DB >> 2013441

Clear cell carcinoma of the endometrium: a histopathological and clinical study of 97 cases.

V M Abeler1, K E Kjørstad.   

Abstract

In a histopathologic review of 1985 cases of endometrial carcinoma 97 patients (4.9%) had clear cell carcinoma (CCC). Mean age at diagnosis was 65.3 years. The crude 5- and 10-year survivals for all stages were 42.3 and 30.9%, respectively. Fifty-nine percent of the patients in surgicopathological stage I and 27% in stage II survived 5 years. Myometrial infiltration and vessel invasion were important prognosticators. Ninety percent of the patients with intramucosal tumors survived 5 years, in contrast to only 15% of the patients with deep myometrial infiltration. Seventeen percent of the patients with vessel invasion survived 5 years, in contrast to 49% of the patients without this finding. CCC is one of the most aggressive subtypes of endometrial carcinoma.

Entities:  

Mesh:

Year:  1991        PMID: 2013441     DOI: 10.1016/0090-8258(90)90279-t

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  25 in total

1.  Clinicopathologic features and treatment in patients with early stage uterine clear cell carcinoma: A 16-year experience.

Authors:  Shannon D Armbruster; Rebecca Previs; Pamela T Soliman; Shannon N Westin; Bryan Fellman; Anuja Jhingran; Nicole D Fleming
Journal:  Gynecol Oncol       Date:  2019-06-18       Impact factor: 5.482

Review 2.  Laboratory Assays in Evaluation of Lynch Syndrome in Patients with Endometrial Carcinoma.

Authors:  Bojana Djordjevic; Russell R Broaddus
Journal:  Surg Pathol Clin       Date:  2016-04-11

Review 3.  Role of the clinical pathology laboratory in the evaluation of endometrial carcinomas for Lynch syndrome.

Authors:  Bojana Djordjevic; Russell R Broaddus
Journal:  Semin Diagn Pathol       Date:  2014-04-02       Impact factor: 3.464

4.  Clear Cell Carcinoma of the Endometrium: Evaluation of Prognostic Parameters in a Multi-institutional Cohort of 165 Cases.

Authors:  Eman Abdulfatah; Sharif Sakr; Sumi Thomas; Zaid Al-Wahab; David G Mutch; Sean Dowdy; Sudeshna Bandyopadhyay; Adnan Munkarah; Mohamed Elshaikh; Robert Morris; Rouba Ali-Fehmi
Journal:  Int J Gynecol Cancer       Date:  2017-10       Impact factor: 3.437

5.  Comparison of outcomes in early-stage uterine clear cell carcinoma and serous carcinoma.

Authors:  Minsi Zhang; T Jonathan Yang; Neil B Desai; Deborah DeLair; Marisa A Kollmeier; Vicky Makker; Mario M Leitao; Nadeem R Abu-Rustum; Kaled M Alektiar
Journal:  Brachytherapy       Date:  2018-10-10       Impact factor: 2.362

6.  Gemcitabine for advanced endometrial cancer: a retrospective study of the Memorial sloan-Kettering Cancer Center experience.

Authors:  Rachel Nicole Grisham; Christina Adaniel; David M Hyman; Weining Ma; Alexia Iasonos; Carol Aghajanian; Jason Konner
Journal:  Int J Gynecol Cancer       Date:  2012-06       Impact factor: 3.437

7.  Morphologic and other clinicopathologic features of endometrial clear cell carcinoma: a comprehensive analysis of 50 rigorously classified cases.

Authors:  Oluwole Fadare; Wenxin Zheng; Marta A Crispens; Howard W Iii Jones; Dineo Khabele; Katja Gwin; Sharon X Liang; Khaled Mohammed; Mohamed M Desouki; Vinita Parkash; Jonathan L Hecht
Journal:  Am J Cancer Res       Date:  2013-01-18       Impact factor: 6.166

8.  Application of Immunohistochemistry and Molecular Diagnostics to Clinically Relevant Problems in Endometrial Cancer Bojana Djordjevic, Shannon Westin, Russell R. Broaddus.

Authors:  Bojana Djordjevic; Shannon Westin; Russell R Broaddus
Journal:  Surg Pathol Clin       Date:  2012-12-01

9.  Proliferative activity in postmenopausal endometrium: the lurking potential for giving rise to an endometrial adenocarcinoma.

Authors:  E Sivridis; A Giatromanolaki
Journal:  J Clin Pathol       Date:  2004-08       Impact factor: 3.411

10.  HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer.

Authors:  G E Konecny; L Santos; B Winterhoff; M Hatmal; G L Keeney; A Mariani; M Jones; C Neuper; B Thomas; L Muderspach; D Riehle; H-J Wang; S Dowdy; K C Podratz; M F Press
Journal:  Br J Cancer       Date:  2008-12-16       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.